Abivax Shares Dip Ahead of Major Scientific Meeting in Chicago

A Decline as Part of Consolidation After an Extraordinary Run

Abivax shares have fallen for the second session, losing 5.36% over seven days. Over three months, the decline reaches 3.99%. This pause comes after an exceptional annual performance, with a 1,398% increase over twelve months. Today's movement occurs in a mixed sector environment. European peers ARGENX SE and GALAPAGOS are down by 2.52% and 2.81% respectively. Across the Atlantic, major companies like Lilly, Johnson & Johnson, and AbbVie are experiencing modest gains. Technically, the price has returned to the lower end of the Bollinger Bands, close to the lower limit set at €89.20. The RSI at 42 remains in a neutral zone, with no clear overbought or oversold signals. The stock is now trading below its 50-day moving average (€102.08) but maintains a comfortable margin above the 200-day moving average at €86.54. The identified support at €88.80 remains the area to watch after the recent declines.

Focus on Digestive Disease Week and the ABTECT Program

The biotech's scientific schedule is packed. Abivax will present nine abstracts on obefazimod at the Digestive Disease Week, held from May 2 to May 5, 2026, in Chicago. The presentations will cover efficacy data, tolerance, and patient feedback from the Phase 3 ABTECT program, as well as preclinical models of antifibrotic activity. This event comes as the stock is under intense analyst scrutiny. In early April, Oddo BHF had raised its price target by 36%, which had fueled renewed interest in the stock. Details of current positions can be viewed on the analyst consensus page. On the financial calendar, the next official milestone is the publication of the first quarter 2026 results, expected on June 1. Until then, the scientific communication in Chicago is the most immediate concrete event for the stock.